Chemotherapies/Targeted Therapies
Tumor Targeting Chemo, Targeted and Combination Therapies
Chemotherapy and targeted cancer therapy are still considered a first line treatment for many cancers. Unfortunately, a limited number of all cancer patients will benefit from current chemo or targeted cancer therapies, leaving a significant need to develop novel combinatorial therapies and strategies that are tumor targeting.
WHY IS TARGETED CANCER THERAPY IMPORTANT?
Kinase inhibition over the last two decades has been a proven approach to treat patients with cancers which have specific genomic attributes, although patients are often prone to relapse due to their cancer evading treatment through other pathways, and conventional chemotherapy is still the frontline tumor targeting treatment for many cancers. Combinations of multiple drugs are often used, as well as the development of multigenerational drugs for known mutations.
Whilst genomic profiling of patients is now commonplace to identify known mutational drivers, many cancers harbor known oncogenic drivers with no currently available targeted therapies, and even genomically well-characterized tumors often have intrinsic resistance to currently available treatments.
We help drug development organizations determine not just the potential efficacy of novel treatments, but also the underlying mechanisms by which patients' tumors evade treatment so as to discover potential targets for new therapies.
Capabilities
Kinase Inhibitor Sunitinib
High content confocal imaging enables the quantitation of tumor cell killing in response to ex vivo treatment of tumoroids with Sunitinib, a multi-targeted receptor kinase inhibitor.
Related Resources
Browse our latest posters and presentations using Nilogen's fresh patient tumoroid technology.
